Aminov Erez 4

What Happened
Erez Aminov, CEO, Chairman and a director of Telomir Pharmaceuticals, acquired 7,319,710 shares of Telomir common stock on April 22, 2026 at an effective price of $1.37 per share, for a total value of $10,028,003. The Form 4 reports the transaction as code “J” (other acquisition), and the filing indicates the shares were issued in exchange for the reporting person’s shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI.

Key Details

• Transaction date: 2026-04-22; Form 4 filed: 2026-04-24 (appears timely — filed within two business days).
• Shares acquired: 7,319,710 at $1.37 per share; total value reported: $10,028,003.
• Transaction code: J — “other acquisition or disposition” (used here for shares issued in an acquisition exchange).
• Footnote: Shares were issued in exchange for the reporting person’s TELI Pharmaceuticals, Inc. shares as part of Telomir’s acquisition of TELI.
• Shares owned after transaction: Not disclosed in the information provided in your request.

Context
This was not an open-market purchase or option exercise but an issuance of stock in connection with an acquisition/merger consideration. Such conversion/exchange transactions reflect deal consideration rather than a direct market signal of the insider’s buying or selling preferences.